Biological dosimetry and Bayesian analysis of chromosomal damage in thyroid cancer patients.

Chromosomal damage was investigated in lymphocytes of thyroid cancer patients after radioiodine treatment. An assay on micronuclei (MN) in binucleated cells was performed in blood samples of 25 patients 3 d after (131)I (3.7 GBq) was given. Statistical analysis does not show overdispersion of the MN distribution, thus considering the exposure to blood as being homogeneous (p < 0.05). A dose-protraction factor (G) of 0.1 was considered into the calculation of the blood dose to take into account the effect of the duration of exposure. The total MN count is a sum of the background distribution and the Poisson distribution induced by radiation exposure. A Bayesian approach was used to avoid inconsistencies when the total count was close to or lower than the background level. Estimated blood dose after 3 d of exposure was 0.73 Gy (0.197 mGy/MBq). The usefulness of the Bayesian method in analysing chromosomal damage when the count is low has been determined.

[1]  M. Schlumberger,et al.  Biological dosimetry in patients treated with iodine-131 for differentiated thyroid carcinoma. , 1996, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[2]  R S Brame,et al.  Bayesian analysis of overdispersed chromosome aberration data with the negative binomial model. , 2002, Radiation protection dosimetry.

[3]  Radioprotective Effects Against Chromosomal Damage Induced in Human Lymphocytes by gamma-Rays as a Function of Polymerization Grade of Grape Seed Extracts. , 2001, Journal of medicinal food.

[4]  R K Sachs,et al.  The link between low-LET dose-response relations and the underlying kinetics of damage production/repair/misrepair. , 1997, International journal of radiation biology.

[5]  H. Thierens,et al.  Adaptive response in patients treated with 131I. , 2000, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[6]  W. Müller,et al.  The micronucleus assay in human lymphocytes after high radiation doses (5-15 Gy). , 2002, Mutation research.

[7]  W Merkle,et al.  Statistical methods in regression and calibration analysis of chromosome aberration data , 1983, Radiation and environmental biophysics.

[8]  J. D. del Río,et al.  Antioxidant activity and radioprotective effects against chromosomal damage induced in vivo by X-rays of flavan-3-ols (Procyanidins) from grape seeds (Vitis vinifera): comparative study versus other phenolic and organic compounds. , 2000, Journal of agricultural and food chemistry.

[9]  Edward L. Frome,et al.  Regression Analysis of Poisson-Distributed Data , 1973 .

[10]  W Schmid,et al.  The micronucleus test. , 1975, Mutation research.

[11]  Carlos D Venencia,et al.  Hospital discharge of patients with thyroid carcinoma treated with 131I. , 2002, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[12]  Estimation of upper limits using a Poisson statistic , 1999, hep-ex/9904025.

[13]  E D Léonard,et al.  Usefulness and limits of biological dosimetry based on cytogenetic methods. , 2005, Radiation protection dosimetry.

[14]  D. van Nostrand,et al.  Dosimetrically determined doses of radioiodine for the treatment of metastatic thyroid carcinoma. , 2002, Thyroid : official journal of the American Thyroid Association.

[15]  D. Lloyd,et al.  Radiation induced chromosome aberrations and the poisson distribution , 1979, Radiation and environmental biophysics.

[16]  R K Sachs,et al.  The linear-quadratic model and most other common radiobiological models result in similar predictions of time-dose relationships. , 1998, Radiation research.

[17]  D. Lloyd,et al.  Criticality accident dosimetry by chromosomal analysis. , 2004, Radiation protection dosimetry.

[18]  C. Acevedo,et al.  Radioprotective-antimutagenic effects of rosemary phenolics against chromosomal damage induced in human lymphocytes by gamma-rays. , 2006, Journal of agricultural and food chemistry.

[19]  C. Villegas,et al.  On the Representation of Ignorance , 1977 .

[20]  D R Shearer,et al.  Effective half-life of 131I in thyroid cancer patients. , 2001, Health physics.

[21]  H. Kanegane,et al.  The radiotoxicity of 131I therapy of thyroid cancer: assessment by micronucleus assay of B lymphocytes. , 2004, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[22]  N. Shuke,et al.  Radiotoxicity after iodine-131 therapy for thyroid cancer using the micronucleus assay. , 1998, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[23]  Albrecht M. Kellerer,et al.  THEORY OF DUAL RADIATION ACTION. , 1972 .

[24]  D. Lea,et al.  The mechanism of the induction by radiation of chromosome aberrations inTradescantia , 1942, Journal of Genetics.

[25]  R G Dale,et al.  The application of the linear-quadratic dose-effect equation to fractionated and protracted radiotherapy. , 1985, The British journal of radiology.

[26]  J. Savage.  Radiation-induced chromosomal aberrations in the plant Tradescantia: Dose-response curves I. Preliminary considerations , 1975 .

[27]  W. Merkle.  Poisson goodness-of-fit tests for radiation-induced chromosome aberrations. , 1981, International journal of radiation biology and related studies in physics, chemistry, and medicine.

[28]  M. Luster,et al.  Comparison of radioiodine biokinetics following the administration of recombinant human thyroid stimulating hormone and after thyroid hormone withdrawal in thyroid carcinoma , 2003, European Journal of Nuclear Medicine and Molecular Imaging.

[29]  D. Lloyd,et al.  The dose response relationship obtained at constant irradiation times for the induction of chromosome aberrations in human lymphocytes by cobalt-60 gamma rays , 1984, Radiation and environmental biophysics.

[30]  G. D'Agostini.  Bayesian inference in processing experimental data: principles and basic applications , 2003 .

[31]  M. Alcaraz,et al.  Radioprotective effects in vivo of phenolics extracted from Olea europaea L. leaves against X-ray-induced chromosomal damage: comparative study versus several flavonoids and sulfur-containing compounds. , 2002, Journal of medicinal food.

[32]  H. Thierens,et al.  Patient dosimetry after 131I-MIBG therapy for neuroblastoma and carcinoid tumours , 2001, Nuclear medicine communications.

[33]  H. Jeffreys,et al.  Theory of probability , 1896 .

[34]  F. Bochud,et al.  Measurement of radioactive samples: application of the Bayesian statistical decision theory , 2005 .

[35]  M. Fenech,et al.  Cytokinesis-block micronucleus method in human lymphocytes: effect of in vivo ageing and low dose X-irradiation. , 1986, Mutation research.

[36]  M. Sonenberg,et al.  The relation of radioiodine dosimetry to results and complications in the treatment of metastatic thyroid cancer. , 1962, The American journal of roentgenology, radium therapy, and nuclear medicine.

[37]  D E Raeside.  Bayesian statistics: a guided tour. , 1976, Medical physics.

[38]  Anne Hoekstra,et al.  Bone marrow dosimetry and safety of high 131I activities given after recombinant human thyroid-stimulating hormone to treat metastatic differentiated thyroid cancer. , 2004, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[39]  Markus Luster,et al.  Iodine biokinetics and dosimetry in radioiodine therapy of thyroid cancer: procedures and results of a prospective international controlled study of ablation after rhTSH or hormone withdrawal. , 2006, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[40]  M. Fenech,et al.  HUman MicroNucleus project: international database comparison for results with the cytokinesis‐block micronucleus assay in human lymphocytes: I. Effect of laboratory protocol, scoring criteria, and host factors on the frequency of micronuclei , 2001, Environmental and molecular mutagenesis.

[41]  M. Sapienza,et al.  131I EFFECTIVE HALF-LIFE (Teff) FOR PATIENTS WITH THYROID CANCER , 2006, Health physics.